The 510(k) pathway changes a company's risk profile at several points, and the insurance program should move with it rather than after it. Decisions made before submission, during review, and at first commercial shipment each carry consequences that are difficult to unwind later.
This is less a single product than a sequencing question. A company needs different protection while it is running a study than it needs the day the first cleared unit ships to a hospital. This page covers the coverage that matters at each stage of the pathway and the requirements that tend to arrive with clearance.
Coverage Before And During Submission
Management liability usually comes first, because the board forms and outside capital arrives well before the device does. If a clinical study supports the submission, clinical trials liability is required before the first site will activate.
The operational coverages build alongside. Property and equipment as the facility and tooling come together, and cyber as the company accumulates study data, design files, and regulatory correspondence that would be damaging to lose or expose.
What Changes At Clearance
Products liability becomes the central coverage the moment the device can be sold. Alongside it, hospital and distributor agreements arrive carrying insurance schedules that specify limits, additional insured status, and certificate requirements.
Recall exposure also becomes real for the first time. Once units are in the field, the company owns the cost of getting them back if a correction is required, and that cost does not sit inside the products liability policy.
Common Sequencing Mistakes
The most frequent is buying products liability late, after a distribution agreement has already been signed to terms the current program does not satisfy. The second is letting clinical trials coverage lapse without a tail, leaving study subject claims that surface later without a policy to answer them.
The third is treating clearance as a paperwork milestone rather than a risk event. Policies written for a pre-revenue company frequently do not contemplate commercial distribution at all, and renewing them unchanged after clearance leaves the largest new exposure uncovered.
Get a coverage review
Want to discuss this coverage for your specific situation? Start a coverage review and we'll respond within one business day with structural observations and a clear next step.